Minoryx presents topline results from Phase 2/3 “ADVANCE” study demonstrating significant clinical benefit of leriglitazone in adrenomyeloneuropathy (AMN)

Minoryx presents topline results from…

Minoryx’s clinical candidate leriglitazone shows clinical benefit in a proof of concept Phase 2 study in Friedreich´s ataxia

Minoryx’s clinical candidate leriglitazone shows…

Immunic, Inc. Added to NASDAQ Biotechnology Index

Immunic, Inc. Added to NASDAQ…

eTheRNA and China Grand Pharma enter a strategic collaboration in the Greater China Region focussed on eTheRNA’s proprietary mRNA development products and manufacturing capabilities

eTheRNA and China Grand Pharma…

Minoryx’s preclinical data for leriglitazone in Friedreich’s Ataxia published in Neurobiology of Disease Journal

Minoryx’s preclinical data for leriglitazone…

ExeVir Bio Appoints Michel Kazatchkine and Stef Heylen to the Board of Directors

ExeVir Bio Appoints Michel Kazatchkine…

Immunic, Inc. Announces 200 Patients Enrolled in Its Phase 2 CALVID-1 Trial of IMU-838 for the Treatment of Moderate COVID-19, Allowing for Main Phase 2 Efficacy Analysis to Proceed

Immunic, Inc. Announces 200 Patients…

European Investment Bank provides Minoryx with up to €25 million to support development of breakthrough therapies in orphan neurodegenerative diseases

European Investment Bank provides Minoryx…

EIB Provides Immunic With up to €24.5 Million to Support Ongoing Development of a Potential COVID-19 Therapy

EIB Provides Immunic With up…

Confo Therapeutics Announces Selection of First Product Candidate and Initiation of Pre-Clinical Development

Confo Therapeutics Announces Selection of…